Burges Salmon has previously advised Cumulus on a £1.7 million investment round and on a significant investment fundraise of c. LDC will act as the drug discovery arm of Nodus and participate in the development of all assets in Nodus’ pipeline.įounded in 2017, Cumulus sources novel oncology assets from academic institutes, commercial drug discovery groups and biopharmaceutical companies. Other key members of the Nodus team include Luis Toledo, PhD, Scientific Founder and Advisor, Nicola Broughton PhD, MBA, Chief Business Officer, Manuelle Debunne PhD, Chief Operating Officer and Scott Doak, Finance Director.įounded in 2008, LDC was established as a novel approach to capitalise on the potential of excellent basic research for the discovery of new therapies for diseases with high medical need. With more than 30 years’ experience in leading successful R&D programmes as well as extensive and in-depth oncology expertise, including in the DDR field, Dr Waddell brings the expertise needed to develop and deliver Nodus’ pipeline successfully. It is led by Chief Executive Officer Dr Ian Waddell PhD. Nodus was founded by Cumulus Oncology and in partnership with the Lead Discovery Center (LDC). goal NODUS intervenes, specifically, in the domains of financial systems. The firm’s Corporate Finance team has advised Nodus, founded by Cumulus Oncology and in partnership with the Lead Discovery Centerīurges Salmon’s Corporate Finance team has advised biotech company Nodus Oncology, a novel biotech company, on its strategic acquisition of certain oncology based IP assets from Basilea Pharmaceutica International AG, which will assist Nodus in developing oncology based molecules inhibiting novel DNA damage. is an international consulting firm founded in 2004.
0 kommentar(er)
